Meinol's new platform - Bonding Chemistry debut in Shanghai IDC

Exhibition content
The 4th IDC2023 Research and Development Forum on New and Improved Drugs (IDC) will be held in Shanghai on March 23-24, 2023. The conference will focus on innovative technologies of new chemical drugs, hot therapeutic areas, and research and development of improved new drugs. As the "backbone" in the field of small molecule CRO/CDMO, Meinol Pharma actively participated and set up a booth. At the same time, it brought its new platform "Bonding Chemistry" to the public for the first time.

Bonding appearance
Two parallel forums, based on the current hot spots of new chemical drugs, focus on the field of antibodies and small molecules, keep up with the latest trends of the market, grasp the latest technology of the industry, analyze the challenges of local pharmaceutical research and development, and look into the future of China's pharmaceutical industry. These issues are also the original intention of Meinol Pharmaceutical, which has been focusing on the development and production of small molecule drugs for many years. In the autumn of 2022, by integrating years of experience and good reputation in the research and development, process optimization and production, quality control and other aspects of small molecule new drugs, Meinol will strive to create a professional e-commerce service platform focusing on the integration of research and development and production of small molecule drugs: bonding chemistry. Our standing stock of products includes molecular blocks, advanced medical intermediates, apis and synthetic reagents to meet the needs of domestic and international customers in the first time from milligram grade to kilogram grade and even larger scale commercial production.

Hit the spot
During the forum, many attendees gathered in front of the booth. Many upstream and downstream colleagues in the field of CRO/CDMO stopped to consult and ask questions. The business team listened carefully and patiently answered every customer's questions throughout the whole process, demonstrating the resources and strength of the company to meet the needs of customers in all aspects and levels.

About bonding
Bond Chemistry, founded in 2022, is one of the subsidiaries of Suzhou Meinuo Pharmaceutical Technology Co., LTD., focusing on the integrated supporting services of small molecule drug research and development and production, is committed to building an e-commerce service platform connecting supply and demand for global pharmaceutical research and development enterprises. Bonding Chemistry benefits from years of experience and good reputation in small molecule new drug research and development, process optimization and production, quality control and other aspects, and has created flagship product series including molecular blocks, medical intermediates, apis and synthetic reagents, fully meeting the needs of domestic and foreign users from milligram-level to kilogram level, and even larger scale commercial production.